The soluble biomarker calprotectin (a S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab

Arthritis Research and Therapy

Volumn 13, Issue 5, 2011, Pages

  Hammer, Hilde B ^a   Fagerhol, Magne K ^b   Wien, Tale N ^c   Kvien, Tore K ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute phase proteins; Anti tnf treatment; Calprotectin; Rheumatoid arthritis; Ultrasonography

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CALGRANULIN; SERUM AMYLOID A; ANTIRHEUMATIC AGENT; AUTACOID; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; PROTEIN S 100;

ADULT; AGED; ARTICLE; B SCAN; CLINICAL ARTICLE; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; OUTCOME ASSESSMENT; POWER DOPPLER ULTRASONOGRAPHY; RHEUMATOID ARTHRITIS; SYNOVITIS; TREATMENT RESPONSE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DOPPLER FLOWMETRY; ECHOGRAPHY; FOLLOW UP; IMMUNOLOGY; METABOLISM; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTE L1 ANTIGEN COMPLEX; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; S100 PROTEINS; SEVERITY OF ILLNESS INDEX; SYNOVITIS; ULTRASONOGRAPHY, DOPPLER; YOUNG ADULT;

EID: 83455210182     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3503     Document Type: Article

References (38)

1. van Leeuwen MA, Westra J, Limburg PC, van Riel PL, van Rijswijk MH. Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study. Ann Rheum Dis 1995, 54:674-677. 10.1136/ard.54.8.674, 1009966, 7677445.
2. de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 2009, 61:1484-1490. 10.1002/art.24838, 19877087.
3. Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir 1980, 16(Suppl):273-281.
4. Edgeworth J, Gorman M, Bennett R, Freemont P, Hogg N. Identification of p8, 14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem 1991, 266:7706-7713.
5. Dale I, Brandtzaeg P, Fagerhol MK, Scott H. Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Am J Clin Pathol 1985, 84:24-34.
6. Andersson KB, Sletten K, Berntzen HB, Dale I, Brandtzaeg P, Jellum E, Fagerhol MK. The leucocyte L1 protein: Identity with the cystic fibrosis antigen and the calcium-binding MRP-8 and MRP-14 macrophage components. Scand J Immunol 1988, 28:241-245. 10.1111/j.1365-3083.1988.tb02437.x, 3413449.
7. Odink K, Cerletti N, Brüggen J, Clerc RG, Tarcsay L, Zwadlo G, Gerhards G, Schlegel R, Sorg C. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 1987, 330:80-82. 10.1038/330080a0, 3313057.
8. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2004, 50:3762-3771. 10.1002/art.20631, 15593206.
9. Loser K, Vogl T, Voskort M, Lueken A, Kupas V, Nacken W, Klenner L, Kuhn A, Foell D, Sorokin L, Luger TA, Roth J, Beissert S. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med 2010, 16:713-717. 10.1038/nm.2150, 20473308.
10. Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF, Dale I. Functional and clinical aspects of the myelomonocyte protein calprotectin. J Clin Pathol: Mol Pathol 1997, 50:113-123.
11. Berntzen HB, Munthe E, Fagerhol MK. A longitudinal study of the leukocyte protein L1 as an indicator of disease activity in patients with rheumatoid arthritis. J Rheumatol 1989, 16:1416-1420.
12. Hammer HB, Odegard S, Fagerhol MK, Landewé R, van der Heijde D, Uhlig T, Mowinckel P, Kvien TK. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis 2007, 66:1093-1097. 10.1136/ard.2006.064741, 1954700, 17234650.
13. Berntzen HB, Ölmez T, Fagerhol MK, Munthe E. The leukocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 1991, 20:74-82. 10.3109/03009749109165280, 1709519.
14. Hammer HB, Ødegård S, Syversen SW, Landewé R, van der Heijde D, Uhlig T, Mowinckel P, Kvien TK. Calprotectin (a major S100 leukocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis 2010, 69:150-154. 10.1136/ard.2008.103739, 19095696.
15. Naredo E, Bonilla G, Gamero F, Uson J, Carmona L, Laffon A A. Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. Ann Rheum Dis 2005, 64:375-381. 1755396, 15708891.
16. Szkudlarek M, Klarlund M, Narvestad E, Court-Payen M, Strandberg C, Jensen KE, Thomsen HS, Østergaard M. Ultrasonography of the metacarpophalangeal and proximal interphalangeal joints in rheumatoid arthritis: a comparison with magnetic resonance imaging, conventional radiography and clinical examination. Arthritis Res Ther 2006, 8:R52. 10.1186/ar1904, 1526591, 16519793.
17. Naredo E, Rodríguez M, Campos C, Rodríguez-Heredia JM, Medina JA, Giner E, Martínez O, Toyos FJ, Ruíz T, Ros I, Pujol M, Miquel X, García L, Aznar JJ, Chamizo E, Páez M, Morales P, Rueda A, Tuneu R, Corominas H, de Agustín JJ, Moragues C, Mínguez D, Willisch A, González-Cruz I, Aragón A, Iglesias G, Armas C, Pablo Valdazo J, Vargas C, et al. Validity, reproducibility, and responsiveness of a twelve-joint simplified power doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. Arthritis Rheum 2008, 59:515-522. 10.1002/art.23529, 18383408.
18. Terslev L, Torp-Pedersen S, Qvistgaard E, Kristoffersen H, Røgind H, Danneskiold-Samsøe B, Bliddal H. Effects of treatment with etanercept (Enbrel, TNRF:Fc) on rheumatoid arthritis evaluated by Doppler ultrasonography. Ann Rheum Dis 2003, 62:178-181. 10.1136/ard.62.2.178, 1754421, 12525391.
19. Filippucci E, Iagnocco A, Salaffi F, Cerioni A, Valesini G, Grassi W. Power Doppler sonography monitoring of synovial perfusion at the wrist joints in patients with rheumatoid arthritis treated with adalimumab. Ann Rheum Dis 2006, 65:1433-1437. 10.1136/ard.2005.044628, 1798349, 16504996.
20. Iagnocco A, Filippucci E, Perella C, Ceccarelli F, Cassarà E, Alessandri C, Sabatini E, Grassi W, Valesini G. Clinical and ultrasonographic monitoring of response to adalimumab treatment in rheumatoid arthritis. J Rheumatol 2008, 35:35-40.
21. Hammer HB, Bolton-King P, Bakkeheim V, Berg TH, Sundt E, Kongtorp AK, Haavardsholm EA. Examination of intra-and inter-rater reliability with a new ultrasonographic reference atlas for scoring of synovitis in patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:1995-1998. 10.1136/ard.2011.152926, 21784724.
22. Hammer HB, Kvien TK. Comparisons of 7- to 78-joint ultrasonography scores: all different joint combinations show equal response to adalimumab treatment in patients with rheumatoid arthritis. Arthritis Res Ther 2011, 13:R78. 10.1186/ar3341, 3218888, 21619619.
23. Hammer HB, Sveinsson M, Kongtorp AK, Kvien TK. A 78-joints ultrasonographic assessment is associated to clinical assessments and is highly responsive to improvement in a longitudinal study of patients with rheumatoid arthritis starting adalimumab treatment. Ann Rheum Dis 2010, 69:1349-1351. 10.1136/ard.2009.126995, 20472599.
24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
25. Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998, 35:745-753.
26. Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992, 27:793-798. 10.3109/00365529209011186, 1411288.
27. Kristinsson J, Røseth A, Fagerhol MK, Aadland E, Schjønsby H, Børmer OP, Raknerud N, Nygaard K. Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum 1998, 41:316-321. 10.1007/BF02237485, 9514426.
28. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107, 7818570.
29. Backhaus M, Burmester GR, Gerber T, Grassi W, Machold KP, Swen WA, Wakefield RJ, Manger B. Guidelines for musculoskeletal ultrasound in rheumatology. Working Group for Musculoskeletal Ultrasound in the EULAR Standing Committee on International Clinical Studies including Therapeutic Trials. Ann Rheum Dis 2001, 60:641-649. 10.1136/ard.60.7.641, 1753749, 11406516.
30. Youssef P, Roth J, Frosch M, Costello P, Fitzgerald O, Sorg C, Bresnihan B. Expression of myeloid related proteins (MRP) 8 and 14 and the MRP8/14 heterodimer in rheumatoid arthritis synovial membrane. J Rheumatol 1999, 26:2523-2528.
31. Sunahori K, Yamamura M, Yamana J, Takasugi K, Kawashima M, Yamamoto H, Chazin WJ, Nakatani Y, Yui S, Makino H. The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther 2006, 8:R69. 10.1186/ar1939, 1526633, 16613612.
32. Berntzen HB, Fagerhol MK, Østensen M, Mowinckel P, Høyeraal HM. The L1 protein as a new indicator of inflammatory activity in patients with juvenile rheumatoid arthritis. J Rheumatol 1991, 18:133-138.
33. Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkötter C, Harms E, Sorg C, Roth J. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000, 43:628-637. 10.1002/1529-0131(200003)43:3<628::AID-ANR20>3.0.CO;2-X, 10728757.
34. Kane D, Roth J, Frosch M, Vogl T, Bresnihan B, FitzGerald O. Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. Arthritis Rheum 2003, 48:1676-1685. 10.1002/art.10988, 12794836.
35. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006, 54:3761-3773. 10.1002/art.22190, 17133543.
36. Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J, Stanevicha V, Mihaylova D, Ferriani V, Tsakalidou FK, Foeldvari I, Cuttica R, Gonzalez B, Ravelli A, Khubchandani R, Oliveira S, Armbrust W, Garay S, Vojinovic J, Norambuena X, Gamir ML, García-Consuegra J, Lepore L, Susic G, Corona F, Dolezalova P, Pistorio A, Martini A, Ruperto N, Roth J. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010, 303:1266-1273. 10.1001/jama.2010.375, 20371785.
37. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewé R, Listing J, Michaud K, Martin-Mola E, Montie P, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011, 70:404-413. 10.1136/ard.2011.149765, 21292833.
38. Naredo E, Möller I, Cruz A, Carmona L, Carrido J. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Arthritis Rheum 2008, 58:2248-2256. 10.1002/art.23682, 18668537.